AstraZeneca shares turned negative Wednesday after a Brazilian health authority said a volunteer in its coronavirus vaccine study died.
The Federal University of Sao Paulo, which is helping coordinate late-stage trials in Brazil, separately said that the volunteer was Brazilian, according to Reuters. Shares of AstraZeneca, a front-runner in the Covid-19 vaccine race, gave up a slight gain after the news broke. Shares were down by about 1% in early afternoon trading. AstraZeneca did not immediately respond to a request for comment. In a statement, a spokesperson from the University of Oxford, which is developing the vaccine with AstraZeneca, said “there have been no concerns about safety of the clinical trial” after an assessment of the case in Brazil. “The independent review in addition to the Brazilian regulator have recommended that the trial should continue,” Oxford spokesperson Alexander Buxton said.
Oxford provided no further details on the volunteer’s death. Brazil currently has the second deadliest outbreak in the world, behind the United States, with at least 115,914 deaths, according to data compiled by Johns Hopkins University.
The news comes as the Food and Drug Administration still has a late-stage clinical trial from AstraZeneca on hold in the United States. That means the company is unable to administer second doses of its two-dose vaccine regimen to U.S. participants.
The company announced on Sept. 8 that its trial had been put on hold due to an unexplained illness in a patient in the United Kingdom. The patient is believed to have developed inflammation of the spinal cord, known as transverse myelitis. The trial has since resumed in the U.K. and other countries but is still on hold in the U.S.
The U.S. is expected to resume the trial as early as this week after the FDA completed its review, Reuters reported Tuesday, citing four anonymous sources. AstraZeneca is one of four drugmakers backed by the U.S. in late-stage testing for a potential vaccine. AstraZeneca’s vaccine, called AZD1222, uses genetic material from the coronavirus with a modified adenovirus. In July, the company published data that showed its vaccine produced a promising immune response in an early-stage trial and appeared to be well tolerated.
The vaccine produced no serious adverse events in volunteers, according to the researchers at the time. Fatigue and headache were the most commonly reported side effects, they said. Other common side effects included pain at the injection site, muscle ache, chills and a fever.